GlassScriptPhysician profile
Suzanne Elshafey
NPI 1942659339
$4,079.67
in general payments reported to CMS, 2019-2025
13 companies · $281 in 2025
The $281 reported for 2025 was less than what a typical Transplant Hepatology provider received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $682 · 2023: $2,214 · 2024: $785 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,280.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,057.13 | 2022-2024 | |
| Boston Scientific Corporation | $977.36 | 2023-2025 | Overstitch Endoscopic Suturing System, Apollo Esg System, Resolution 360 Clip |
| Gilead Sciences, INC. | $490.42 | 2022-2023 | Epclusa |
| Janssen Scientific Affairs, LLC | $274.19 | 2022-2024 | Stelara |
| Cook Medical LLC | $264.92 | 2023 | Echotip |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $242.18 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $229.67 | 2023 | Ocaliva |
| Medtronic, INC. | $172.70 | 2022 | |
| Qol Medical, LLC | $121.17 | 2023 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $118.52 | 2023 | Gattex |
| Ipsen Biopharmaceuticals, INC | $63.01 | 2025 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $49.22 | 2025 | Rezdiffra |
| Lilly USA, LLC | $19.18 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Elshafey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.